Infusion is scheduled—but is the authorization actually complete?

Treatment sites often schedule appointments while authorization work is still underway. That may be reasonable operationally, but patients should know whether the coverage path is complete before a high-cost dose is administered.

CMS rules increasingly require certain payers to make prior-authorization decisions within defined timeframes, but the patient still needs the actual decision for the specific service.

Ask for status in precise language

Instead of asking “is everything good?”, ask whether prior authorization is approved, pending, not required or denied. If approved, ask for the authorization number, dates, product, dose/units and site.

If the clinic says “no authorization required,” ask whether that statement came from the payer and whether any product-preference or medical-policy criteria still apply.

Confirm the exact product that will be given

For biologics with biosimilars or multiple formulations, the authorization may name a specific product. The treatment site should compare the ordered and stocked product with the approved product before administration.

If a specialty pharmacy is involved, confirm the shipment and administration authorization separately.

If approval is still pending, make an informed scheduling decision

Ask the clinic what happens if the payer has not decided by the appointment time. Do not assume the patient must accept financial responsibility for an unresolved payer process without understanding the treatment site’s policy.

If the case is clinically urgent, the prescriber can ask whether expedited review is appropriate.

Use the source that actually controls your case

MedicineCostHelp can organize the problem, but the member-specific plan, payer decision, provider record or assistance program makes the actual determination. Keep written decisions, reference numbers and the documents that support the next step.